BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director John Schmid bought 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the transaction, the director owned 6,000 shares in the company, valued at $96,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
BlossomHill Therapeutics Price Performance
BlossomHill Therapeutics stock traded down $0.01 during mid-day trading on Monday, hitting $15.99. The company’s stock had a trading volume of 417,968 shares. BlossomHill Therapeutics, Inc. has a 12 month low of $15.25 and a 12 month high of $17.25.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
